8-K: Anebulo Reports Q1 FY26 Results, Advances Pediatric Drug

Anebulo Pharmaceuticals announced its first quarter fiscal year 2026 financial results and provided updates on its lead drug candidate, selonabant, for pediatric cannabis toxicity.

Summary

• Reported Q1 FY2026 financial results for the period ended September 30, 2025.
• Initiated a Phase 1 single ascending dose (SAD) study of an intravenous (IV) formulation of selonabant for acute cannabis-induced toxicity in children on September 25, 2025.
• Awarded the second-year tranche of $994,300 from a collaborative grant by the National Institute on Drug Abuse (NIDA) for the ongoing SAD study.
• Prioritizing the IV formulation of selonabant for pediatric patients due to the serious nature of the condition and potential for a faster timeline to approval compared to the adult oral product.
• Net loss for Q1 FY2026 was $2.2 million, or $(0.05) per share, consistent with the prior year's $2.2 million loss but improved per share from $(0.08).
• Cash and cash equivalents stood at $10.4 million as of September 30, 2025, with access to an additional $3.0 million via a Loan Agreement.
• A proposed going private transaction, including a reverse stock split, is under review, with a further announcement expected by year-end.
• The government shutdown has delayed the ability to resolve SEC comments on the proxy statement for the reverse stock split.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company continues to report a net loss and faces delays with its strategic transaction, significant progress in clinical development for a high-need pediatric indication, securing grant funding, and positive FDA interactions provide a strong positive counterbalance. The financial results are stable, and the strategic shift to pediatric IV formulation is a calculated move for faster approval.

Positives

• Initiation of Phase 1 SAD study for IV selonabant in pediatric cannabis toxicity, addressing a significant unmet medical need.
• Award of a $994,300 grant from NIDA, providing non-dilutive funding for the SAD study.
• FDA has suggested close collaboration to facilitate the development of selonabant for pediatric cannabis toxicity.
• Net loss per share improved to $(0.05) from $(0.08) year-over-year, despite a similar net loss, indicating better capital efficiency or share structure.
• Operating expenses slightly decreased to $2.3 million from $2.4 million year-over-year.

Negatives

• The company continues to report a net loss of $2.2 million for the quarter.
• Cash and cash equivalents decreased to $10.4 million as of September 30, 2025, from $11.6 million as of June 30, 2025.
• Delay in holding the special meeting for the proposed reverse stock split due to the government shutdown impacting SEC comment resolution on the proxy statement.
• Uncertainty surrounding the proposed going private transaction and strategic alternatives review process, with no assurance of a transaction.

Risks

• Ability to pursue regulatory strategy, including the Phase 1 SAD study of intravenous selonabant.
• The ability of selonabant to be a potential treatment for pediatric patients with cannabis-induced poisoning.
• The ability of selonabant to rapidly reverse key symptoms of cannabis toxicity.
• Ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements.
• Ability to obtain or maintain the capital or grants necessary to fund research and development activities.
• Ability to complete clinical trials on time and achieve desired results and benefits as expected.
• Regulatory limitations relating to the ability to promote or commercialize product candidates for specific indications.
• Acceptance of product candidates in the marketplace and the successful development, marketing or sale of products.
• Ability to maintain license agreements and the continued maintenance and growth of its patent estate.
• Ability to retain key employees.
• Ability to successfully complete a going private transaction, with no assurance that the process will result in a transaction.
• The Board can determine to abandon the Reverse Stock Split and hold the special meeting at any time.

Future Outlook

The company anticipates selonabant will rapidly reverse key symptoms of acute cannabis-induced toxicity. It expects to make a further announcement regarding the strategic alternatives review process, including the proposed going private transaction and reverse stock split, by the end of this year. The observational study in Emergency Departments is being amended to focus on pediatric patients.

Management Comments

• "We have made significant progress towards our goal of providing the first emergency antidote for acute cannabis-induced toxicity in children."
• "In addition to the continuing collaborative support from NIDA, our interactions with the Food and Drug Administration to date have confirmed our belief that there is a significant and growing unmet need for a treatment for children exposed to cannabis toxicity."
• "FDA has suggested a close collaboration with Anebulo to facilitate the development of selonabant for this important pediatric condition."
• "If approved, we believe selonabant has the potential to offer a much-needed targeted therapy for rapidly reversing the serious and life-threatening consequences of acute cannabis-induced toxicity in children."

Industry Context

The focus on an intravenous formulation for pediatric acute cannabis-induced toxicity positions Anebulo in a niche but growing area within the pharmaceutical industry, driven by increasing cannabis legalization and accidental pediatric exposures. This strategy aims for a faster regulatory pathway compared to adult indications, potentially addressing a critical unmet need where current treatments are largely supportive rather than targeted antidotes. The NIDA grant and FDA collaboration underscore the recognized public health importance of this specific indication.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential impact from the proposed reverse stock split and going private transaction, which could alter ownership structure and liquidity. Delays in the special meeting create uncertainty.
• Patients (Pediatric): Potential for a novel, targeted treatment (selonabant IV) for acute cannabis-induced toxicity, addressing a serious unmet medical need.
• Employees: Continued progress in drug development and grant funding may provide stability, but the uncertainty of a "going private" transaction could introduce future changes.
• Regulatory Bodies (FDA, NIDA): Continued collaboration with FDA and NIDA grant support indicates alignment with public health priorities and regulatory guidance.

Next Steps

• Continue the Phase 1 SAD study of intravenous selonabant.
• Amend the ongoing observational study in Emergency Departments to focus on pediatric patients.
• The Board expects to make a further announcement regarding the strategic alternatives review process by the end of this year.
• Hold a special meeting of stockholders to approve the reverse stock split, once SEC comments on the proxy statement are resolved.

Key Dates

Recommendation

The company shows promising clinical progress in a high-need area (pediatric cannabis toxicity) with positive FDA engagement and non-dilutive grant funding. However, the ongoing net losses, decreasing cash balance, and significant uncertainty surrounding the proposed "going private" transaction and its associated reverse stock split, including delays due to government shutdown, introduce considerable risk. Investors should hold to monitor the outcome of the strategic review and the progress of the IV selonabant clinical trials before making further investment decisions. The potential for a going private transaction could limit future upside for public shareholders if the terms are not favorable.

Keywords

Anebulo Pharmaceuticals, ANEB, Selonabant, Cannabis Toxicity, Pediatric Treatment, Acute Cannabinoid Intoxication, CB1 Antagonist, Clinical Trial, Phase 1 SAD Study, IV Formulation, NIDA Grant, SEC Filing, Financial Results, Biotechnology, Pharmaceuticals, Drug Development, Going Private Transaction, Reverse Stock Split